Quality of life and functioning in first‐episode psychosis <scp>C</scp>hinese patients with different antipsychotic medications

H, Lee; Hui, Christy Lai Ming; Lin, J.; Ching, Elaine Y.N.; Chang, Wing Chung; Chen, Eric

doi:10.1111/eip.12246

Cited by 5 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with results of previous studies on chronic schizophrenia (Awad et al, 1997;Browne et al, 1998;Hofer et al, 2004), we found that antipsychotic-induced akathisia and negative attitude toward antipsychotic treatment were associated with poorer mental SQoL. This echoes findings of our prior research on adult-onset FEP which demonstrated differential relationships of various antipsychotics with SQoL, with those medications having higher propensity to induce extrapyramidal side-effects being related to lower SQoL (Lee et al, 2015). In fact, akathisia, which is characterized by motor and subjective inner restlessness, has been regarded as one of the most distressing antipsychotic-induced movement disorders (Poyurovsky, 2010).…”

Section: Discussionsupporting

confidence: 92%

Clinical and treatment-related determinants of subjective quality of life in patients with first-episode psychosis

Kwong

Chang

Chan

et al. 2017

Psychiatry Research

View full text Add to dashboard Cite

Subjective quality of life (SQoL) has been increasingly studied in first-episode psychosis (FEP). Prior research primarily examined the impact of psychiatric symptoms on SQoL. Relationship between treatment-related factors and SQoL is under-studied. In this study, 159 Chinese patients who had completed 2-year treatment from early intervention service in Hong Kong were recruited. Assessments on premorbid adjustment, clinical profiles including social anxiety measure, functioning, antipsychotic-induced extrapyramidal side-effects and attitude toward medication treatment were conducted. SQoL was evaluated by Chinese version SF36 which generated mental and physical component summary (MCS and PCS) scores for analysis. Our results showed that more severe positive symptoms, higher level of depression, greater social anxiety, more negative attitude toward antipsychotic medications and greater degree of akathisia independently predicted lower MCS score. Higher social anxiety level and poorer functioning predicted lower PCS score. Our results indicate that affective and positive symptoms, functioning, and treatment-related variables are critical determinants of SQoL in FEP patients. These identified factors thus represent potentially malleable therapeutic targets for early detection and prompt intervention to promote enhancement of SQoL in the early stage of illness.

show abstract

Section: Discussionsupporting

confidence: 92%

Clinical and treatment-related determinants of subjective quality of life in patients with first-episode psychosis

Kwong

Chang

Chan

et al. 2017

Psychiatry Research

View full text Add to dashboard Cite

show abstract

“…The majority of studies included second-or third-generation antipsychotic medications. In particular, 29 studies (26.1%) analyzed first-generation antipsychotics (FGAs), with haloperidol being the most studied drug [53,[79][80][81][82][83][84][85][86], while flupentixol was the most studied among first-generation depot antipsychotics [50,51,55,87]. The vast majority of papers (71.8%, 79 out of 110 papers) on the efficacy of second-generation antipsychotics (SGAs) included the assessment of quality of life as an outcome measure.…”

Section: Study Selection and Data Extractionmentioning

confidence: 99%

A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia

Sampogna,

Di Vincenzo,

Giuliani

et al. 2023

Brain Sciences

View full text Add to dashboard Cite

Pharmacological antipsychotic drug interventions represent the cornerstone of the management of patients with schizophrenia and other psychotic spectrum disorders. The choice of the “best” treatment should be made on the basis of several clinical domains. However, despite available treatments, the quality of life reported by patients with schizophrenia taking antipsychotics is still very poor, and this outcome is rarely taken into account in trials assessing the efficacy and effectiveness of antipsychotic treatments. Therefore, we performed a systematic review in order to assess the impact of antipsychotic treatment on patients’ quality of life. In particular, we aimed to identify any differences in the improvement in quality of life according to the (a) type of formulation of antipsychotic drugs (i.e., oral vs. depot vs. long-acting injectable); (b) type of the drug (first vs. second vs. third generation); and (c) patients’ clinical characteristics. One hundred and eleven papers were included in the review. The main findings were as follows: (1) quality of life is usually considered a secondary outcome in trials on the efficacy and effectiveness of drugs; (2) second-generation antipsychotics have a more positive effect on quality of life; and (3) long-acting injectable antipsychotics are associated with a more stable improvement in quality of life and with a good safety and tolerability profile. Our systematic review confirms that quality of life represents a central element for selecting the appropriate treatment for people with schizophrenia. In particular, the availability of new treatments with a better tolerability profile, a proven effectiveness on patients’ cognitive and social functioning, and with a more stable blood concentration might represent the appropriate strategy for improving the quality of life of people with schizophrenia.

show abstract

“…In literature from high‐income countries, FEP has been associated with sociodemographic factors such as male sex, increased urbanicity, ethnic minority, trauma exposure, and poor diet (Aucoin et al, 2018; Mbewe et al, 2006; O'Donoghue et al, 2016; Santesteban‐Echarri et al, 2017; Sauve et al, 2018; Tomassi & Tosato, 2017; Tournier, 2013; van der Ven et al, 2012). It has also been shown that patients with FEP have a poorer quality of life than their healthy peers (Lee et al, 2016; Ohmuro et al, 2017; Watson et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Comparison of antipsychotic naïve first‐episode psychosis patients and healthy controls in Uganda

Mwesiga

Akena

Koen

et al. 2021

Early Intervention Psych

View full text Add to dashboard Cite

Introduction The risk factors for a first episode of psychosis in low and middle‐income countries (LMICs) are not well described. The study compared the association of different risk factors in patients with first‐episode psychosis patients and healthy controls from an LMIC context. Methods A comparative, descriptive, cross‐sectional study was performed in antipsychotic naïve first‐episode psychosis patients and healthy controls at the National referral hospital in Uganda. Standardized tools were used to assess sociodemographic (e.g., age, sex, socioeconomic status) and clinical (e.g., childhood trauma, quality of life) variables. First episode psychosis participants were compared to healthy controls in terms of sociodemographic and clinical variables, and logistic regression was used to determine predictors of FEP. Results Our final sample included 198 antipsychotic naïve first‐episode psychosis participants and 82 controls. Most participants were female (68.5%) with a mean age of 29.4 years. After adjusting for age and sex, FEP patients when compared to controls were less likely to be female [AOR 0.18 (95%CI 0.03–0.85; p = .031)], more likely to have experienced emotional abuse [AOR 1.30 (95%CI 1.02–1.65; p = .032)] and more likely to have a poor quality of life [AOR 0.93 (95%CI 0.89–0.97; p = .002)]. Discussion The risk factors for a first episode of psychosis in this low and middle‐income population were like those described in high‐income countries. Further studies on interventions to prevent the transition to psychotic disorders in this sub‐groups of patients are recommended. Also, the use of specialized early intervention services in improving the quality of life needs to be evaluated.

show abstract

Quality of life and functioning in first‐episode psychosis Chinese patients with different antipsychotic medications

Cited by 5 publications

References 32 publications

Clinical and treatment-related determinants of subjective quality of life in patients with first-episode psychosis

Clinical and treatment-related determinants of subjective quality of life in patients with first-episode psychosis

A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia

Comparison of antipsychotic naïve first‐episode psychosis patients and healthy controls in Uganda

Contact Info

Product

Resources

About